AIM
PCRX icon

Acrospire Investment Management’s Pacira BioSciences PCRX Stock Holding History

Acrospire Investment Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-172
Closed -$8K – 1030
2017
Q2 		$8K Sell
172
-1,500
-90% -$69.6K 0.01% 1861
2017
Q1 		$76K Sell
1,672
-6,728
-80% -$291K 0.06% 530
2016
Q4 		$271K Buy
8,400
+4,200
+100% +$140K 0.11% 185
2016
Q3 		$144K Buy
4,200
+4,000
+2,000% +$157K 0.1% 293
2016
Q2 		$7K Buy
+200
New +$9.83K 0.01% 1815

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Acrospire Investment Management's PCRX Position: Q3 2017 in Review

Acrospire Investment Management sold out of Pacira BioSciences (PCRX) in Q3 2017, closing a stake of 172 shares — an estimated $8K sold.

Acrospire Investment Management first reported a position in PCRX in Q2 2016 and held it in 5 quarters. The position peaked at $271K in Q4 2016. 180 funds tracked by Wall St. Rank hold PCRX as of Q3 2017.

  • Acrospire Investment Management reported no remaining Pacira BioSciences position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 172 Pacira BioSciences shares in Q3 2017, an estimated $8K.
  • Acrospire Investment Management first reported a position in Pacira BioSciences in Q2 2016 and held it in 5 quarters.
  • Acrospire Investment Management's Pacira BioSciences position peaked at $271K in Q4 2016.
  • 180 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.